118 related articles for article (PubMed ID: 33417268)
21. Insights from the WHO and National Lists of Essential Medicines: Focus on Pediatric Diabetes Care in Africa.
Rowlands A; Ameyaw E; Rutagarama F; Dipesalema J; Majaliwa ES; Mbogo J; Ogle GD; Chanoine JP
Horm Res Paediatr; 2018; 90(2):82-92. PubMed ID: 30048982
[TBL] [Abstract][Full Text] [Related]
22. The availability of essential medicines for diabetes at health facilities in Bangladesh: evidence from 2014 and 2017 national surveys.
Hakim S; Chowdhury MAB; Ahmed NU; Uddin MJ
BMC Health Serv Res; 2022 Mar; 22(1):377. PubMed ID: 35317808
[TBL] [Abstract][Full Text] [Related]
23. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
Chow CK; Ramasundarahettige C; Hu W; AlHabib KF; Avezum A; Cheng X; Chifamba J; Dagenais G; Dans A; Egbujie BA; Gupta R; Iqbal R; Ismail N; Keskinler MV; Khatib R; Kruger L; Kumar R; Lanas F; Lear S; Lopez-Jaramillo P; McKee M; Mohammadifard N; Mohan V; Mony P; Orlandini A; Rosengren A; Vijayakumar K; Wei L; Yeates K; Yusoff K; Yusuf R; Yusufali A; Zatonska K; Zhou Y; Islam S; Corsi D; Rangarajan S; Teo K; Gerstein HC; Yusuf S;
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):798-808. PubMed ID: 30170949
[TBL] [Abstract][Full Text] [Related]
24. Essential medicines for COPD and asthma in low and middle-income countries.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
Thorax; 2014 Dec; 69(12):1149-51. PubMed ID: 24590803
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region.
Mehrtash H; Laing R; Wirtz VJ
East Mediterr Health J; 2018 Jul; 24(5):427-434. PubMed ID: 30043961
[TBL] [Abstract][Full Text] [Related]
26. Association of Socioeconomics With Prevalence of Visual Impairment and Blindness.
Wang W; Yan W; Müller A; Keel S; He M
JAMA Ophthalmol; 2017 Dec; 135(12):1295-1302. PubMed ID: 29049446
[TBL] [Abstract][Full Text] [Related]
27. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
28. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia.
Kaiser AH; Hehman L; Forsberg BC; Simangolwa WM; Sundewall J
PLoS One; 2019; 14(12):e0226169. PubMed ID: 31834889
[TBL] [Abstract][Full Text] [Related]
29. Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and Uganda.
Baldeh AO; Millard C; Pollock AM; Brhlikova P
J Pharm Policy Pract; 2023 Jan; 16(1):18. PubMed ID: 36717871
[TBL] [Abstract][Full Text] [Related]
30. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.
Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP
J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557
[TBL] [Abstract][Full Text] [Related]
31. Organizational barriers associated with the implementation of national essential medicines policy: A cross-sectional study of township hospitals in China.
Yang L; Liu C; Ferrier JA; Zhang X
Soc Sci Med; 2015 Nov; 145():201-8. PubMed ID: 26360408
[TBL] [Abstract][Full Text] [Related]
32. Access to medicines through health systems in low- and middle-income countries.
Ozawa S; Shankar R; Leopold C; Orubu S
Health Policy Plan; 2019 Dec; 34(Supplement_3):iii1-iii3. PubMed ID: 31816069
[TBL] [Abstract][Full Text] [Related]
33. Access to essential medicines to treat chronic respiratory disease in low-income countries.
Bissell K; Perrin C; Beran D
Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
[TBL] [Abstract][Full Text] [Related]
34. Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.
Beran D; Ewen M; Lipska K; Hirsch IB; Yudkin JS
Curr Diab Rep; 2018 Jun; 18(8):48. PubMed ID: 29907884
[TBL] [Abstract][Full Text] [Related]
35. Does economic growth reduce childhood stunting? A multicountry analysis of 89 Demographic and Health Surveys in sub-Saharan Africa.
Yaya S; Uthman OA; Kunnuji M; Navaneetham K; Akinyemi JO; Kananura RM; Adjiwanou V; Adetokunboh O; Bishwajit G
BMJ Glob Health; 2020; 5(1):e002042. PubMed ID: 32133174
[TBL] [Abstract][Full Text] [Related]
36. Mapping actions to improve access to medicines for mental disorders in low and middle income countries.
Barbui C; Dua T; Kolappa K; Saraceno B; Saxena S
Epidemiol Psychiatr Sci; 2017 Oct; 26(5):481-490. PubMed ID: 28067194
[TBL] [Abstract][Full Text] [Related]
37. Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial.
Rockers PC; Laing RO; Ashigbie PG; Onyango MA; Mukiira CK; Wirtz VJ
Lancet Glob Health; 2019 Apr; 7(4):e492-e502. PubMed ID: 30799142
[TBL] [Abstract][Full Text] [Related]
38. Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India.
Satheesh G; Sharma A; Puthean S; Ansil T P M; E J; Raj Mishra S; Unnikrishnan MK
Trop Med Int Health; 2020 Dec; 25(12):1467-1479. PubMed ID: 32959441
[TBL] [Abstract][Full Text] [Related]
39. Use of medical services and medicines attributable to type 2 diabetes care in Yaoundé, Cameroon: a cross-sectional study.
Mapa-Tassou C; Fezeu LK; Njoumemi Z; Lontchi-Yimagou E; Sobngwi E; Mbanya JC
BMC Health Serv Res; 2017 Apr; 17(1):262. PubMed ID: 28399869
[TBL] [Abstract][Full Text] [Related]
40. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.
Mendis S; Fukino K; Cameron A; Laing R; Filipe A; Khatib O; Leowski J; Ewen M
Bull World Health Organ; 2007 Apr; 85(4):279-88. PubMed ID: 17546309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
